Detalles de la búsqueda
1.
Identification of potential immune-related mechanisms related to the development of multiple myeloma.
Chin Med J (Engl);
2024 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38844445
2.
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting.
Expert Opin Biol Ther;
24(5): 321-326, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38717336
3.
A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody.
Sci Rep;
14(1): 10661, 2024 05 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38724599
4.
Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes.
J Cancer Res Clin Oncol;
150(4): 189, 2024 Apr 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38605258
5.
Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting.
Expert Opin Biol Ther;
24(4): 221-223, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38506624
6.
Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy.
Drug Resist Updat;
74: 101068, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38402670
7.
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting.
Exp Hematol Oncol;
13(1): 25, 2024 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38413984
8.
Functional characterization of D-type cyclins involved in cell division in rice.
BMC Plant Biol;
24(1): 157, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38424498
9.
Immune cells in the B-cell lymphoma microenvironment: From basic research to clinical applications.
Chin Med J (Engl);
137(7): 776-790, 2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38269619
10.
Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.
BMC Cancer;
24(1): 124, 2024 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38267866
11.
Targeting TIGIT for cancer immunotherapy: recent advances and future directions.
Biomark Res;
12(1): 7, 2024 Jan 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38229100
12.
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions.
Cancer Immunol Immunother;
73(2): 31, 2024 Jan 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38279998
13.
Clinical metagenomic sequencing of plasma microbial cell-free DNA for febrile neutropenia in patients with acute leukaemia.
Clin Microbiol Infect;
30(1): 107-113, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37271194
14.
Unbiased Single-Cell Sequencing of Hematopoietic and Immune Cells from Aplastic Anemia Reveals the Contributors of Hematopoiesis Failure and Dysfunctional Immune Regulation.
Adv Sci (Weinh);
11(10): e2304539, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38145351
15.
Single VHH-directed BCMA CAR-NK cells for multiple myeloma.
Exp Hematol Oncol;
12(1): 98, 2023 Nov 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38012722
16.
A new prognostic risk model for acute myeloid leukemia patients based on telomere-related genes.
Leuk Res;
135: 107404, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37844405
17.
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies.
Exp Hematol Oncol;
12(1): 92, 2023 Oct 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37845755
18.
IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy.
Antib Ther;
6(4): 240-252, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37846296
19.
Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments.
Chin Med J (Engl);
2023 Aug 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37640679
20.
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
J Hematol Oncol;
16(1): 92, 2023 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37537597